Moreover, from our cohorts 2, we also found patients’ overall survival (OS) and progression-free survival (PFS) were significantly poorer in ccRCC with high MYH9 levels (Fig. 2e, f, Supplementary Table S5). This evidence concerns the gene MYH9 and nonpapillary renal cell carcinoma.